A Phase 1/2, Multicenter, First in Human, Dose Escalation and Expansion Study Evaluating CHM-029, as Monotherapy and in Combination with Standard Therapies in Participants with Relapsed or Refractory, or Newly Diagnosed Acute Myeloid Leukemia (AML) with NPM1 Mutations, KMT2A or NUP98 Rearrangements

Principal Investigator

Prof Paresh Vyas

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1014076